(J) Crystal violet viability assay of M238R cells treated with BRAFi/MEKi (BRAFi, Vemurafenib and MEKi, Trametinib) (1 µM), BIBF (2 μM) or with BRAFi/MEKi (1 μM) plus BIBF (2 μM) for 72 h. Paired Student t-test was used for statistical analysis. ****P≤0.0001. Significance was calculated against the control group. Statistical significance of BIBF vs BIBF + BRAFi/MEKi was also calculated. Data is represented as mean ± SD from a triplicate representative of 3 independent experiments. 